---
document_datetime: 2025-12-02 06:31:24
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/xenical.html
document_name: xenical.html
version: success
processing_time: 0.1336685
conversion_datetime: 2025-12-26 20:27:22.293923
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Xenical

[RSS](/en/individual-human-medicine.xml/66401)

##### Authorised

This medicine is authorised for use in the European Union

orlistat Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Xenical](#news-on)
- [More information on Xenical](#more-information-on-xenical-1305)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

Expand section

Collapse section

## What is Xenical?

Xenical is a medicine containing the active substance orlistat. It is available as turquoise capsules (120 mg).

## What is Xenical used for?

Xenical is used together with dieting for the treatment of obese (very overweight) patients with a body mass index (BMI) greater than or equal to 30 kg per square metre, or overweight patients (BMI greater than or equal to 28 kg/m 2 ) who are at risk of illness because of their weight.

The medicine can only be obtained with a prescription.

## How is Xenical used?

Xenical is given as one capsule taken with water just before, during, or up to one hour after each main meal. If a meal is missed or contains no fat, Xenical should not be taken. The patient should be on a diet in which about 30% of the calories come from fat, and which is rich in fruit and vegetables. The food in the diet should be spread over three main meals.

Treatment with Xenical should be stopped after 12 weeks if patients have been unable to lose at least 5% of their body weight since the start of treatment.

## How does Xenical work?

The active ingredient in Xenical, orlistat, is an anti-obesity medicine, which does not affect appetite. Orlistat blocks gastrointestinal lipases (enzymes that digest fat). When these enzymes are blocked, they cannot digest some fats in the diet, and this allows about 30% of the fat eaten in the meal to pass through the gut undigested. The body cannot use this dietary fat for energy or convert it into fat tissue. This helps weight reduction.

## How has Xenical been studied?

The effects of Xenical were first tested in experimental models before being studied in humans.

Xenical has been studied in seven main studies involving over 3,000 overweight or obese patients. The studies lasted from one to two years and compared three different doses of Xenical with placebo (a dummy treatment), in combination with dieting. Neither the patients nor the doctors knew which treatment each patient was taking until the end of the study. An additional longer study in over 3,000 obese patients compared the effects of Xenical and placebo over four years, in combination with diet and exercise. In all studies, the main measure of effectiveness was the change in weight.

## What benefit has Xenical shown during the studies?

Xenical was more effective than placebo in producing a reduction in weight. When the results from all seven shorter studies were taken together, patients taking 120 mg Xenical three times a day had an average fall of 6.1 kg in body weight after a year, compared with 2.6 kg in those taking placebo. The proportion of patients losing 10% or more of their body weight was 20% in the patients taking this dose of Xenical and 8% in those taking placebo. At the end of the four-year study, 21% of the patients treated with Xenical had lost more than 10% of their body weight, compared with 10% of the patients who received placebo.

## What is the risk associated with Xenical?

The most common side effects with Xenical (seen in more than 1 patient in 10) are influenza (flu), hypoglycaemia (low blood sugar levels), headache, upper respiratory infection (colds), oily spotting from the rectum, abdominal (tummy) pain or discomfort, flatus (gas) with discharge, faecal urgency (urgent need to open the bowels), fatty or oily stools, flatulence (gas), liquid stools, oily evacuation (faeces) and increased defecation. These symptoms generally occur at the beginning of treatment, and go away after some time. For the full description of all side effects reported with Xenical, see the package leaflet.

Xenical should not be used in people who may be hypersensitive (allergic) to orlistat or any of the other ingredients. It should also not be used in people with a long-term malabsorption disease (where nutrients from the food are not easily absorbed during digestion), with cholestasis (a liver disorder) or who are breast-feeding.

## Why has Xenical been approved?

The Committee for Medicinal Products for Human Use (CHMP) decided that Xenical's benefits are greater than its risks in conjunction with a mildly hypocalorific diet for the treatment of obese patients with a BMI greater or equal to 30 kg/m 2 , or overweight patients (BMI ? 28 kg/m 2 ) with associated risk factors. The Committee recommended that Xenical be given marketing authorisation.

## Other information about Xenical

The European Commission granted a marketing authorisation valid throughout the European Union for Xenical to Roche Registration Limited on 29 July 1998. The marketing authorisation was renewed on 29 July 2003 and on 29 July 2008.

Xenical : EPAR - Summary for the public

English (EN) (81.48 KB - PDF)

**First published:** 13/11/2008

**Last updated:** 13/11/2008

[View](/en/documents/overview/xenical-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-868)

български (BG) (175.16 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/bg/documents/overview/xenical-epar-summary-public_bg.pdf)

español (ES) (86.01 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/es/documents/overview/xenical-epar-summary-public_es.pdf)

čeština (CS) (163.18 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/cs/documents/overview/xenical-epar-summary-public_cs.pdf)

dansk (DA) (87.4 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/da/documents/overview/xenical-epar-summary-public_da.pdf)

Deutsch (DE) (91.4 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/de/documents/overview/xenical-epar-summary-public_de.pdf)

eesti keel (ET) (83.44 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/et/documents/overview/xenical-epar-summary-public_et.pdf)

ελληνικά (EL) (191.42 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/el/documents/overview/xenical-epar-summary-public_el.pdf)

français (FR) (43.01 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/fr/documents/overview/xenical-epar-summary-public_fr.pdf)

italiano (IT) (84.87 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/it/documents/overview/xenical-epar-summary-public_it.pdf)

latviešu valoda (LV) (165.08 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/lv/documents/overview/xenical-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (158.73 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/lt/documents/overview/xenical-epar-summary-public_lt.pdf)

magyar (HU) (153.43 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/hu/documents/overview/xenical-epar-summary-public_hu.pdf)

Malti (MT) (166.06 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/mt/documents/overview/xenical-epar-summary-public_mt.pdf)

Nederlands (NL) (87.27 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/nl/documents/overview/xenical-epar-summary-public_nl.pdf)

polski (PL) (169.17 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/pl/documents/overview/xenical-epar-summary-public_pl.pdf)

português (PT) (82.04 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/pt/documents/overview/xenical-epar-summary-public_pt.pdf)

română (RO) (153.24 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/ro/documents/overview/xenical-epar-summary-public_ro.pdf)

slovenčina (SK) (159.08 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/sk/documents/overview/xenical-epar-summary-public_sk.pdf)

slovenščina (SL) (149.16 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/sl/documents/overview/xenical-epar-summary-public_sl.pdf)

Suomi (FI) (84.65 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/fi/documents/overview/xenical-epar-summary-public_fi.pdf)

svenska (SV) (86.79 KB - PDF)

**First published:**

13/11/2008

**Last updated:**

13/11/2008

[View](/sv/documents/overview/xenical-epar-summary-public_sv.pdf)

## Product information

Xenical : EPAR - Product Information

English (EN) (362.94 KB - PDF)

**First published:** 04/05/2009

**Last updated:** 10/05/2023

[View](/en/documents/product-information/xenical-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-195)

български (BG) (499.52 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/bg/documents/product-information/xenical-epar-product-information_bg.pdf)

español (ES) (336.49 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/es/documents/product-information/xenical-epar-product-information_es.pdf)

čeština (CS) (490.83 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/cs/documents/product-information/xenical-epar-product-information_cs.pdf)

dansk (DA) (399.85 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/da/documents/product-information/xenical-epar-product-information_da.pdf)

Deutsch (DE) (398.08 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/de/documents/product-information/xenical-epar-product-information_de.pdf)

eesti keel (ET) (339.13 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/et/documents/product-information/xenical-epar-product-information_et.pdf)

ελληνικά (EL) (506.2 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/el/documents/product-information/xenical-epar-product-information_el.pdf)

français (FR) (343.85 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/fr/documents/product-information/xenical-epar-product-information_fr.pdf)

hrvatski (HR) (365.99 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/hr/documents/product-information/xenical-epar-product-information_hr.pdf)

íslenska (IS) (351.03 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/is/documents/product-information/xenical-epar-product-information_is.pdf)

italiano (IT) (314.83 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/it/documents/product-information/xenical-epar-product-information_it.pdf)

latviešu valoda (LV) (369.56 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/lv/documents/product-information/xenical-epar-product-information_lv.pdf)

lietuvių kalba (LT) (437.15 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/lt/documents/product-information/xenical-epar-product-information_lt.pdf)

magyar (HU) (462.71 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/hu/documents/product-information/xenical-epar-product-information_hu.pdf)

Malti (MT) (348.35 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/mt/documents/product-information/xenical-epar-product-information_mt.pdf)

Nederlands (NL) (406.47 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/nl/documents/product-information/xenical-epar-product-information_nl.pdf)

norsk (NO) (364.16 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/no/documents/product-information/xenical-epar-product-information_no.pdf)

polski (PL) (404.31 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/pl/documents/product-information/xenical-epar-product-information_pl.pdf)

português (PT) (370.25 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/pt/documents/product-information/xenical-epar-product-information_pt.pdf)

română (RO) (472.48 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/ro/documents/product-information/xenical-epar-product-information_ro.pdf)

slovenčina (SK) (414.43 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/sk/documents/product-information/xenical-epar-product-information_sk.pdf)

slovenščina (SL) (370.3 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/sl/documents/product-information/xenical-epar-product-information_sl.pdf)

Suomi (FI) (338.71 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/fi/documents/product-information/xenical-epar-product-information_fi.pdf)

svenska (SV) (380.55 KB - PDF)

**First published:**

04/05/2009

**Last updated:**

10/05/2023

[View](/sv/documents/product-information/xenical-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0088 10/05/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Xenical : EPAR - All Authorised presentations

English (EN) (86.91 KB - PDF)

**First published:** 19/12/2005

**Last updated:** 19/12/2013

[View](/en/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-361)

български (BG) (104.35 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/bg/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_bg.pdf)

español (ES) (87.92 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/es/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_es.pdf)

čeština (CS) (103.88 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/cs/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (89.3 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/da/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (87.17 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/de/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (87.17 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/et/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (105.47 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/el/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_el.pdf)

français (FR) (87.09 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/fr/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (100.44 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/hr/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (88.49 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/is/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_is.pdf)

italiano (IT) (86.91 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/it/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (101.66 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/lv/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (103.32 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/lt/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (103.72 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/hu/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (103.01 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/mt/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (86.69 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/nl/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (87.99 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/no/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_no.pdf)

polski (PL) (103.38 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/pl/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_pl.pdf)

português (PT) (88.42 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/pt/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_pt.pdf)

română (RO) (102.68 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/ro/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (101.99 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/sk/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (91.68 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/sl/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (87.62 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/fi/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (87.81 KB - PDF)

**First published:**

19/12/2005

**Last updated:**

19/12/2013

[View](/sv/documents/all-authorised-presentations/xenical-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Xenical Active substance orlistat International non-proprietary name (INN) or common name orlistat Therapeutic area (MeSH) Obesity Anatomical therapeutic chemical (ATC) code A08AB01

### Pharmacotherapeutic group

Antiobesity preparations, excl. diet products

### Therapeutic indication

Xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m 2 , or overweight patients (BMI &gt; 28 kg/m 2 ) with associated risk factors.

Treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight as measured at the start of therapy.

## Authorisation details

EMA product number EMEA/H/C/000154 Marketing authorisation holder

CHEPLAPHARM Arzneimittel GmbH

Ziegelhof 24

Marketing authorisation issued 29/07/1998 Revision 25

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Xenical : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (261.79 KB - PDF)

**First published:** 04/05/2009

**Last updated:** 10/05/2023

[View](/en/documents/procedural-steps-after/xenical-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Xenical-H-C-PSUSA-00002220-201502 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/772580/2015

English (EN) (73.42 KB - PDF)

**First published:** 22/01/2016

**Last updated:** 22/01/2016

[View](/en/documents/scientific-conclusion/xenical-h-c-psusa-00002220-201502-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Xenical-H-C-154-PSU-17 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/CHMP/256042/2013

English (EN) (63.51 KB - PDF)

**First published:** 19/12/2013

**Last updated:** 19/12/2013

[View](/en/documents/scientific-conclusion/xenical-h-c-154-psu-17-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Xenical-H-C-000154-A-20-0057 : EPAR - Assessment Report

Adopted

Reference Number: EMA/276626/2012

English (EN) (216.25 KB - PDF)

**First published:** 21/11/2012

**Last updated:** 21/11/2012

[View](/en/documents/variation-report/xenical-h-c-000154-20-0057-epar-assessment-report_en.pdf)

Xenical-H-C-000154-A-20-0059 : EPAR - Assessment Report

Adopted

Reference Number: EMA/568019/2012

English (EN) (112.46 KB - PDF)

**First published:** 21/11/2012

**Last updated:** 21/11/2012

[View](/en/documents/variation-report/xenical-h-c-000154-20-0059-epar-assessment-report_en.pdf)

Xenical : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (84.02 KB - PDF)

**First published:** 19/12/2005

**Last updated:** 19/12/2005

[View](/en/documents/steps-after-cutoff/xenical-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Xenical : EPAR - Procedural steps taken before authorisation

English (EN) (90.17 KB - PDF)

**First published:** 19/12/2005

**Last updated:** 19/12/2005

[View](/en/documents/procedural-steps/xenical-epar-procedural-steps-taken-authorisation_en.pdf)

Xenical : EPAR - Scientific Discussion

English (EN) (217.23 KB - PDF)

**First published:** 19/12/2005

**Last updated:** 19/12/2005

[View](/en/documents/scientific-discussion/xenical-epar-scientific-discussion_en.pdf)

#### News on Xenical

[European Medicines Agency finalises review of medicines concerned by Roche pharmacovigilance inspection](/en/news/european-medicines-agency-finalises-review-medicines-concerned-roche-pharmacovigilance-inspection) 19/11/2013

[European Medicines Agency starts infringement procedure to investigate Roche's alleged non-compliance with pharmacovigilance obligations](/en/news/european-medicines-agency-starts-infringement-procedure-investigate-roches-alleged-non-compliance-pharmacovigilance-obligations) 23/10/2012

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 July 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-july-2012) 20/07/2012

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 February 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-february-2012) 17/02/2012

[European Medicines Agency confirms positive benefit-risk balance of orlistat-containing medicines](/en/news/european-medicines-agency-confirms-positive-benefit-risk-balance-orlistat-containing-medicines) 16/02/2012

[European Medicines Agency starts review of orlistat-containing medicines](/en/news/european-medicines-agency-starts-review-orlistat-containing-medicines) 22/09/2011

#### More information on Xenical

Questions and answers on the review of centrally authorised medicines with ingredients manufactured at Roche Carolina Inc., Florence, United States

Reference Number: EMA/476366/2012

English (EN) (81.91 KB - PDF)

**First published:** 20/07/2012

**Last updated:** 20/07/2012

[View](/en/documents/medicine-qa/questions-and-answers-review-centrally-authorised-medicines-ingredients-manufactured-roche-carolina-inc-florence-united-states_en.pdf)

Questions and answers on the review of orlistat-containing medicines

Adopted

Reference Number: EMA/CHMP/113837/2012 Rev.1

English (EN) (80.64 KB - PDF)

**First published:** 16/02/2012

**Last updated:** 21/12/2012

[View](/en/documents/referral/questions-and-answers-review-orlistat-containing-medicines_en.pdf)

[Other languages (21)](#file-language-dropdown-829)

български (BG) (118.59 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/bg/documents/referral/questions-and-answers-review-orlistat-containing-medicines_bg.pdf)

español (ES) (99.92 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/es/documents/referral/questions-and-answers-review-orlistat-containing-medicines_es.pdf)

čeština (CS) (123.82 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/cs/documents/referral/questions-and-answers-review-orlistat-containing-medicines_cs.pdf)

dansk (DA) (95.06 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/da/documents/referral/questions-and-answers-review-orlistat-containing-medicines_da.pdf)

Deutsch (DE) (98.67 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/de/documents/referral/questions-and-answers-review-orlistat-containing-medicines_de.pdf)

eesti keel (ET) (121.07 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/et/documents/referral/questions-and-answers-review-orlistat-containing-medicines_et.pdf)

ελληνικά (EL) (126.31 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/el/documents/referral/questions-and-answers-review-orlistat-containing-medicines_el.pdf)

français (FR) (99.07 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/fr/documents/referral/questions-and-answers-review-orlistat-containing-medicines_fr.pdf)

italiano (IT) (117.49 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/it/documents/referral/questions-and-answers-review-orlistat-containing-medicines_it.pdf)

latviešu valoda (LV) (120.32 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/lv/documents/referral/questions-and-answers-review-orlistat-containing-medicines_lv.pdf)

lietuvių kalba (LT) (120.89 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/lt/documents/referral/questions-and-answers-review-orlistat-containing-medicines_lt.pdf)

magyar (HU) (113.19 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/hu/documents/referral/questions-and-answers-review-orlistat-containing-medicines_hu.pdf)

Malti (MT) (122.96 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/mt/documents/referral/questions-and-answers-review-orlistat-containing-medicines_mt.pdf)

Nederlands (NL) (95.18 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/nl/documents/referral/questions-and-answers-review-orlistat-containing-medicines_nl.pdf)

polski (PL) (112.17 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/pl/documents/referral/questions-and-answers-review-orlistat-containing-medicines_pl.pdf)

português (PT) (86.42 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/pt/documents/referral/questions-and-answers-review-orlistat-containing-medicines_pt.pdf)

română (RO) (113.38 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/ro/documents/referral/questions-and-answers-review-orlistat-containing-medicines_ro.pdf)

slovenčina (SK) (112.48 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/sk/documents/referral/questions-and-answers-review-orlistat-containing-medicines_sk.pdf)

slovenščina (SL) (108.67 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/sl/documents/referral/questions-and-answers-review-orlistat-containing-medicines_sl.pdf)

Suomi (FI) (95.69 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/fi/documents/referral/questions-and-answers-review-orlistat-containing-medicines_fi.pdf)

svenska (SV) (86.83 KB - PDF)

**First published:**

16/02/2012

**Last updated:**

21/12/2012

[View](/sv/documents/referral/questions-and-answers-review-orlistat-containing-medicines_sv.pdf)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 10/05/2023

## Share this page

[Back to top](#main-content)